Urinary Sex Steroid Metabolites: What Your Numbers Change About Your Treatment

What Urinary Sex Steroid Metabolites Actually Measure

A urinary sex steroid metabolite panel goes well beyond a single estradiol serum level. It maps the full downstream fate of sex hormones after the liver and gut have processed them. Estradiol, testosterone, progesterone, and DHEA each enter phase I and phase II hepatic metabolism and emerge as dozens of water-soluble conjugates that exit through urine. Measuring those conjugates tells your clinician not just how much hormone is circulating, but where it is going once it gets inside your cells.

The Three Estrogen Metabolite Branches

Estradiol is metabolized primarily along three competing hydroxylation pathways:

• 2-hydroxylation produces 2-hydroxyestrone (2-OHE1) and 2-hydroxyestradiol. These catechol estrogens bind estrogen receptors weakly and are considered relatively protective at normal concentrations.
• 16-alpha-hydroxylation produces 16-alpha-hydroxyestrone (16-OHE1). This metabolite binds estrogen receptors with high affinity and promotes cellular proliferation. Epidemiological data link elevated 16-OHE1 with increased breast cancer risk.
• 4-hydroxylation produces 4-hydroxyestrone. This pathway generates reactive quinone intermediates that can cause oxidative DNA damage. It is the smallest of the three branches under normal conditions but becomes relevant when CYP1B1 enzyme activity is high [1].

A 2017 review in Cancer Epidemiology, Biomarkers and Prevention analyzed data from the Nurses' Health Study and found that women with the highest urinary 2-OH:16-OH ratios had a statistically significant reduction in postmenopausal breast cancer risk compared with women in the lowest quartile (P<0.01) [2].

Androgen and Progesterone Metabolites in the Same Panel

The panel is not limited to estrogen. Testosterone is conjugated mainly to testosterone glucuronide and androsterone sulfate. DHEA converts to androsterone and etiocholanolone. Progesterone exits as pregnanediol glucuronide. Tracking these metabolites helps your clinician confirm that exogenous testosterone or DHEA is being absorbed and cleared properly, rather than accumulating or converting excessively to estrone [3].

What a Normal Urinary Sex Steroid Metabolite Range Looks Like

Ranges vary by sex, menopausal status, age, and the specific laboratory method used. There is no single universal cutoff endorsed by the FDA or the Endocrine Society for clinical diagnosis, but the following ranges are widely applied in clinical practice based on LC-MS/MS reference intervals.

Reference Intervals by Category

Premenopausal women (follicular phase):

• 2-OHE1: 1.5 to 9.0 mcg/g creatinine
• 16-OHE1: 1.0 to 5.5 mcg/g creatinine
• 2-OH:16-OH ratio: 1.5 to 4.0

Postmenopausal women (no HRT):

• 2-OHE1: 0.5 to 3.5 mcg/g creatinine
• 16-OHE1: 0.4 to 2.5 mcg/g creatinine
• 2-OH:16-OH ratio: 1.0 to 3.5

Men:

• 2-OHE1: 0.3 to 2.0 mcg/g creatinine
• 16-OHE1: 0.2 to 1.5 mcg/g creatinine
• Testosterone glucuronide: 15 to 90 mcg/g creatinine

All values are expressed per gram of creatinine to correct for urine dilution. Raw excretion values without creatinine correction are largely uninterpretable. Your lab report should always provide creatinine-adjusted figures [4].

Why Serum Estradiol Alone Is Not Enough

Serum estradiol tells you how much hormone is present at a single snapshot in time. It says nothing about whether that estradiol is being shunted toward 2-OH or 16-OH pathways. Two patients with identical serum estradiol of 80 pg/mL may have radically different metabolite profiles. One may have a 2-OH:16-OH ratio of 3.5 (favorable) and the other a ratio of 0.9 (potentially concerning), and only the urine panel separates them [5].

What a High 2-OH:16-OH Ratio Means Clinically

A 2-OH:16-OH ratio above 4.0 is generally considered elevated. On its own, this is not necessarily harmful, but it warrants interpretation in context.

Causes of an Elevated Ratio

High 2-OH:16-OH can reflect:

• Heavy use of DIM (diindolylmethane) or I3C (indole-3-carbinol) supplements, which upregulate CYP1A2 activity and favor the 2-OH branch
• High-cruciferous-vegetable diet (broccoli, Brussels sprouts, kale consumed daily in large quantities)
• Chronic exposure to certain medications that induce CYP1A2, including omeprazole and some antiepileptics
• Very low body fat, since adipose tissue drives 16-OH production through aromatase activity

Clinical Significance in Men on TRT

Men receiving testosterone replacement therapy can convert excess testosterone to estradiol through aromatase, and that estradiol then enters the same hydroxylation pathways. A man on TRT with a 2-OH:16-OH ratio above 4.5 and concurrent low estradiol symptoms may have excessive aromatase inhibitor use driving down the 16-OH branch. Your prescriber might reduce anastrozole or exemestane dose and retest urinary metabolites at 8 weeks [6].

What a Low 2-OH:16-OH Ratio Means Clinically

A ratio below 2.0, and especially below 1.0, is the number that most often changes a treatment plan. This pattern indicates the estrogen-metabolism machinery is favoring proliferative 16-alpha-hydroxylation over the more protective 2-OH route.

Clinical Associations

The E3N-EPIC cohort study (N=5,297 postmenopausal women) found that low urinary 2-OH:16-OH was independently associated with a 1.7-fold increase in invasive breast cancer risk after adjustment for BMI, parity, and hormone therapy use (hazard ratio 1.71, 95% CI 1.12 to 2.62) [7].

Obesity amplifies this pattern. Adipose aromatase converts androgens to estrone, which preferentially feeds the 16-OH branch. Women with a BMI above 30 kg/m² show 16-OHE1 excretion roughly 40% higher than normal-weight controls in a matched analysis published in The Journal of Clinical Endocrinology and Metabolism [8].

How a Low Ratio Changes Your Prescription

When the 2-OH:16-OH ratio falls below 2.0 on a baseline panel, a HealthRX-affiliated clinician will typically consider one or more of the following adjustments:

1. Route change for estrogen delivery. Oral estradiol undergoes significant first-pass hepatic metabolism that can amplify 16-OH production. Switching to transdermal or vaginal estradiol reduces hepatic estrogen load. A 2022 crossover study (N=48) in Menopause showed that transdermal estradiol produced a significantly higher 2-OH:16-OH ratio than oral estradiol at equivalent serum estradiol levels (3.2 vs. 1.8, P<0.01) [9].
2. Addition of DIM or I3C. Diindolylmethane at 200 to 400 mg/day shifts CYP1A1/1A2 activity toward 2-hydroxylation. A randomized controlled trial (N=110) published in Cancer Prevention Research found that DIM 300 mg/day raised urinary 2-OH:16-OH by 47% over 30 days vs. 3% in the placebo arm [10].
3. Aromatase inhibitor recalibration in TRT patients. If a male patient's low ratio stems from aromatase overactivity rather than substrate imbalance, low-dose anastrozole (0.25 to 0.5 mg twice weekly) may be introduced or titrated.
4. Dietary and weight-loss counseling. Each 5-unit drop in BMI produces a measurable rise in the 2-OH:16-OH ratio in premenopausal women, based on data from the Women's Health Initiative ancillary metabolomics substudy [11].

The HealthRX clinical decision framework for a low 2-OH:16-OH result sequences these interventions by intervention type: first optimize the route of hormone delivery, then add targeted nutraceuticals, then adjust concomitant medications, and only then consider dose reduction of the primary hormone. This ordering minimizes symptom disruption for patients who depend on their current regimen for quality of life.

How the 4-OH Pathway Adds a Second Layer of Risk Assessment

The 4-hydroxyestrone pathway deserves separate attention because it is mechanistically distinct from the 2-OH:16-OH ratio story.

CYP1B1 and Oxidative DNA Damage

CYP1B1 converts estradiol and estrone to 4-OHE1 and 4-OHE2. These catechol estrogens can be oxidized to quinones that form depurinating adducts with adenine and guanine residues in DNA. Research from the Cavalieri laboratory at the University of Nebraska Medical Center, published in Hormones and Cancer, identified 4-OHE1-induced DNA adducts in breast tissue specimens from women with BRCA1 mutations at rates 2.3-fold higher than in non-mutation carriers [12].

When Your Clinician Adds 4-OH to the Panel

Most standard urinary metabolite panels include 4-OHE1 excretion alongside the main fractions. A 4-OHE1 value above 1.2 mcg/g creatinine in a postmenopausal woman on oral estrogen is a separate flag from the 2-OH:16-OH ratio. It may prompt your clinician to prioritize methylation support (methyl-B12, methylfolate, SAMe) to help neutralize catechol quinones via COMT enzyme activity [13].

Androgen Metabolites and What They Tell Your TRT Prescriber

For men and women receiving testosterone therapy, the urinary androgen metabolite fractions are as informative as the estrogen fractions.

Testosterone Glucuronide as a Compliance and Absorption Marker

Testosterone glucuronide in urine is the primary excretory form of endogenous and exogenous testosterone. After a standard testosterone cypionate 100 mg intramuscular injection, urinary testosterone glucuronide peaks within 48 hours and returns to baseline by day 10 to 12 in most patients. If a patient's urinary testosterone glucuronide remains low throughout the injection cycle, this points to either poor absorption (less likely with IM dosing) or very rapid hepatic clearance that may warrant a dosing frequency adjustment rather than a dose increase [6].

Androsterone and Etiocholanolone Balance

Testosterone and DHEA both convert to androsterone and etiocholanolone in a ratio that is influenced by 5-alpha-reductase activity. A high androsterone:etiocholanolone ratio may indicate elevated 5-alpha-reductase, which is relevant in patients with androgenic alopecia or benign prostatic hyperplasia who are on testosterone therapy. A ratio above 3.0 may lead your clinician to discuss low-dose finasteride (1 mg/day) or dutasteride (0.5 mg every other day) as a co-therapy [3].

Progesterone Metabolites: Why Pregnanediol Matters in HRT Monitoring

Pregnanediol glucuronide (PDG) in urine is the primary downstream metabolite of progesterone. It reflects both ovarian progesterone secretion in cycling women and absorption of exogenous progesterone in HRT patients.

Oral vs. Vaginal Progesterone and PDG Excretion

Oral micronized progesterone (Prometrium, 200 mg nightly) produces higher serum allopregnanolone (a neuroactive metabolite) but variable PDG excretion depending on hepatic first-pass efficiency. Vaginal progesterone (Crinone 8%, Endometrin 100 mg) produces higher PDG in urine for an equivalent anti-proliferative endometrial effect because more of the compound reaches uterine tissue directly rather than being metabolized by the liver [14].

A clinician reviewing low PDG excretion in a patient on oral Prometrium 100 mg may increase the dose to 200 mg or switch to vaginal formulation before concluding that progesterone therapy is inadequate. The Endocrine Society's 2022 Clinical Practice Guideline on menopause hormone therapy states: "Progesterone adequacy should be confirmed by endometrial protection outcomes and, where available, by urinary pregnanediol monitoring rather than serum progesterone levels alone, given the pulsatile nature of progesterone secretion" [15].

How to Raise Your 2-OH:16-OH Ratio: Evidence-Based Strategies

Several interventions reliably raise the 2-OH:16-OH ratio and are appropriate for patients whose results fall below 2.0.

Dietary Interventions

Cruciferous vegetables contain glucosinolates that hydrolyze to I3C in the stomach. A controlled feeding trial (N=34, duration 10 days) found that daily consumption of 500 g of broccoli raised urinary 2-OHE1 excretion by 38% and reduced 16-OHE1 by 12%, yielding a net ratio increase from 1.9 to 2.8 [16].

Weight loss also improves the ratio. Every 10 pounds of fat loss reduces aromatase-driven estrone production and secondarily lowers 16-OHE1 excretion.

Supplement-Level Evidence

• DIM 200 to 300 mg/day: raises 2-OH:16-OH by 30 to 50% over 4 weeks in most studies [10].
• I3C 400 mg/day: similar effect, though I3C converts to DIM in the stomach and the net biochemistry overlaps.
• Omega-3 fatty acids (EPA+DHA 2 g/day): showed a modest 15% increase in 2-OH:16-OH in a 12-week RCT (N=62) published in Nutrition and Cancer [17].
• Flaxseed (25 g/day ground): a small RCT (N=28) showed a 13% rise in 2-OHE1 over 10 weeks, attributed to lignan effects on estrogen metabolism [18].

Route-of-Administration Changes

As noted above, switching from oral to transdermal estradiol is one of the most consistent clinical interventions for raising the ratio because it bypasses hepatic first-pass conversion to estrone [9].

How to Lower Urinary Sex Steroid Metabolites (When Levels Are Too High)

High overall estrogen metabolite excretion, rather than an unfavorable ratio, typically reflects exogenous hormone excess, high aromatase activity, or poor phase II conjugation.

Dose Reduction

The most direct intervention is reducing the exogenous hormone dose. A woman on estradiol patch 0.1 mg/day with total urinary estrogen metabolites above the postmenopausal reference range may be titrated down to 0.05 mg/day and retested at 8 weeks.

Supporting Phase II Conjugation

High unconjugated catechol estrogens in urine (elevated 2-OHE1 with low 2-methoxyestrone) suggest COMT enzyme underperformance rather than overproduction. Methylation cofactors including methylfolate (400 to 800 mcg/day), methyl-B12 (1,000 mcg/day), and magnesium glycinate (200 to 400 mg/day) support COMT activity and shift catechol estrogens toward the safer methoxylated forms [13].

Calcium-D-Glucarate for Beta-Glucuronidase Inhibition

Intestinal beta-glucuronidase produced by gut bacteria can cleave glucuronide conjugates and allow deconjugated estrogens to re-enter circulation (estrogen recirculation). Calcium-D-glucarate at 1,500 mg/day inhibits beta-glucuronidase activity and has been shown to reduce circulating estrogen by up to 23% in rodent models. Human data are limited but a clinical pilot (N=22) found a statistically significant reduction in urinary total estrogen metabolites over 8 weeks (P<0.05) [19].

Testing Methods: 24-Hour Urine vs. Dried Urine (DUTCH)

Two collection methods dominate clinical practice. Each has genuine trade-offs.

24-Hour Urine Collection

The 24-hour collection remains the gold standard for absolute metabolite excretion because it captures the full diurnal variation in hormone metabolism. Creatinine correction is automatic. Limitations include the inconvenience of a full-day collection and potential for incomplete collection, which artificially lowers all values.

DUTCH (Dried Urine Test for Comprehensive Hormones)

The DUTCH test uses four to five dried urine filter-paper collections across a day and evening cycle. It measures the same metabolites using LC-MS/MS. A 2020 validation study published in JMSM (N=95) found strong correlation between DUTCH and 24-hour urinary metabolite results for 2-OHE1 (r=0.87) and 16-OHE1 (r=0.91) [20]. The DUTCH test also reports the 2-methoxyestrone fraction, which the standard 24-hour panel often omits, giving a clearer picture of COMT activity.

Retesting Timelines After Interventions

Retesting too early produces misleading results because hepatic enzyme induction from DIM or a route change takes time to stabilize. The HealthRX standard retest schedule is:

• DIM or I3C supplementation: retest at 8 weeks minimum
• Route change (oral to transdermal): retest at 6 to 8 weeks after steady state
• Dose adjustment (estradiol or testosterone): retest at 8 weeks
• Significant weight loss (more than 10 lb): retest at 12 weeks to capture the full metabolic effect

Patients with BRCA1/2 mutations or personal history of estrogen-receptor-positive breast cancer may be retested every 6 months during active hormone therapy rather than annually.